Today, Sanofi-aventis announced the results of new analysis that found a significantly lower risk of nocturnal hypoglycemia with Lantus (insulin glargine [rDNA] injection) as compared to NPH insulin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback